Summary of Study ST003661
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002271. The data can be accessed directly via it's Project DOI: 10.21228/M82V6D This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Download mwTab file (text) | Download mwTab file(JSON) | Download data files (Contains raw data)
| Study ID | ST003661 |
| Study Title | Lipidomics facilitates the discovery of diagnostic biomarkers in patients with chronic total occlusion during the perioperative period |
| Study Summary | Chronic total occlusion (CTO) is a subtype of cardiovascular disease associated with high mortality and an increased risk of ventricular arrhythmia. This study aimed to investigate lipidomic changes in CTO patients undergoing percutaneous coronary intervention (PCI) using a tandem-lipidomic strategy. We first applied a global lipidomic approach to identify the serum lipidomes of CTO-PCI patients during the perioperative period, successfully separating and identifying over 1,500 lipids. Based on these results, a Multiple Reaction Monitoring (MRM) quantification method was developed and employed for targeted lipidomic analysis. Using a high-throughput MRM tandem liquid chromatography-mass spectrometry approach, 613 lipids were successfully quantified in CTO-PCI patients and control donors. PA 18:2/11:0 emerged as a potential biomarker for distinguishing CTO patients from those suspected of having the condition. Notably, patients with different prognostic outcomes exhibited significantly distinct serum lipidomes in both pre- and post-CTO-PCI samples. This finding suggests that lipidomic data hold significant potential not only for monitoring postoperative prognosis but also for predicting surgical outcomes |
| Institute | Zhongshan Hospital Fudan University |
| Last Name | Wang |
| First Name | Zhenxin |
| Address | 136 Yi Xue Yuan Road |
| wang.zhenxin@zs-hospital.sh.cn | |
| Phone | +8618817976583 |
| Submit Date | 2024-12-04 |
| Num Groups | 4 |
| Total Subjects | 63 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | wiff |
| Analysis Type Detail | LC-MS |
| Release Date | 2025-01-20 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR002271 |
| Project DOI: | doi: 10.21228/M82V6D |
| Project Title: | Metabolome trajectory of exercise physiology- a comprehensive study of healthy male and female athletes |
| Project Summary: | BACKGROUND. Integrating metabolomics in sports science provides valuable insights into the biochemistry during physical activity. However, due to their invasiveness, traditional blood sampling methods present challenges in sports settings. The study investigated sex-specific metabolic responses, addressing a significant gap in exercise research, where female participation remains underrepresented. METHODS. To address this, we explored volumetrically accurate microsampling (VAMS) as a dried blood spot (DBS) technique for assessing metabolomic changes in response to acute exercise in more than 130 participants. This study employed a targeted quantitative approach using isotopically-labeled internal standards to measure over 100 metabolites in DBS, providing accurate and traceable results. An accuracy assessment using standard reference material and stability testing over 90 days further evaluated the suitability of DBS for sports metabolomics. RESULTS. Our findings confirm that DBS offers a valid approach to capturing metabolic changes during exercise, reporting a wide panel of metabolites including key metabolites of energy pathways, which correlate well with plasma-derived data but also less studied classes such as pyrimidines. Implementing a straightforward standardization concept established metabolic perturbations upon bout exercise as differences of absolute concentrations. CONCLUSIONS. While metabolic regulations upon exercise are similar in both sexes, differences in the correlation with fitness-related metadata such as peak volitional oxygen consumption (V̇O2peak) and performance, indicate a higher complexity in women and a limitation of previous knowledge to men only. The quantification approach together with the simplicity of the sampling paves the way to expand this type of research towards other fields of personalized medical services. |
| Institute: | University of Vienna |
| Department: | Department of Analytical Chemistry |
| Laboratory: | Koellensperger Lab |
| Last Name: | Schoeny |
| First Name: | Harald |
| Address: | Waehringerstrasse 38 |
| Email: | harald.schoeny@univie.ac.at |
| Phone: | +43 1 4277 52380 |
| Contributors: | Harald Schoeny, Bruno Stelzer, Theresa Hofbauer, Florian Reisenbauer, Yasin El Abiead, Jürgen Scharhag, Gunda Koellensperger |
Subject:
| Subject ID: | SU003794 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
| mb_sample_id | local_sample_id | Degree of coronary artery occlusion | Operation | Sample source |
|---|---|---|---|---|
| SA400956 | CON8 | control | control | Blood serum |
| SA400957 | shotgun-CON 3 | control | control | Blood serum |
| SA400958 | CON1 | control | control | Blood serum |
| SA400959 | CON2 | control | control | Blood serum |
| SA400960 | CON3 | control | control | Blood serum |
| SA400961 | CON4 | control | control | Blood serum |
| SA400962 | CON5 | control | control | Blood serum |
| SA400963 | CON6 | control | control | Blood serum |
| SA400964 | CON7 | control | control | Blood serum |
| SA400965 | CON10 | control | control | Blood serum |
| SA400966 | CON9 | control | control | Blood serum |
| SA400967 | CON11 | control | control | Blood serum |
| SA400968 | CON12 | control | control | Blood serum |
| SA400969 | CON13 | control | control | Blood serum |
| SA400970 | CON14 | control | control | Blood serum |
| SA400971 | CON15 | control | control | Blood serum |
| SA400972 | CON16 | control | control | Blood serum |
| SA400973 | CON17 | control | control | Blood serum |
| SA400974 | CON18 | control | control | Blood serum |
| SA400975 | CON19 | control | control | Blood serum |
| SA400976 | CON20 | control | control | Blood serum |
| SA400977 | shotgun-CON 2 | control | control | Blood serum |
| SA400978 | shotgun-CON 1 | control | control | Blood serum |
| SA400916 | CTO-PCI3 | Disease group | 24 hours after CTO-PCI operation | Blood serum |
| SA400917 | CTO-PCI7 | Disease group | 24 hours after CTO-PCI operation | Blood serum |
| SA400918 | CTO-PCI6 | Disease group | 24 hours after CTO-PCI operation | Blood serum |
| SA400919 | CTO-PCI5 | Disease group | 24 hours after CTO-PCI operation | Blood serum |
| SA400920 | CTO-PCI4 | Disease group | 24 hours after CTO-PCI operation | Blood serum |
| SA400921 | shotgun-POST-24H1 | Disease group | 24 hours after CTO-PCI operation | Blood serum |
| SA400922 | shotgun-POST-24H2 | Disease group | 24 hours after CTO-PCI operation | Blood serum |
| SA400923 | shotgun-POST-24H3 | Disease group | 24 hours after CTO-PCI operation | Blood serum |
| SA400924 | CTO-PCI1 | Disease group | 24 hours after CTO-PCI operation | Blood serum |
| SA400925 | CTO-PCI2 | Disease group | 24 hours after CTO-PCI operation | Blood serum |
| SA400926 | shotgun-POST-72H3 | Disease group | 72 hours after CTO-PCI operation | Blood serum |
| SA400927 | shotgun-POST-72H2 | Disease group | 72 hours after CTO-PCI operation | Blood serum |
| SA400928 | shotgun-POST-72H1 | Disease group | 72 hours after CTO-PCI operation | Blood serum |
| SA400929 | CTO15 | Disease group | pre-operation | Blood serum |
| SA400930 | CTO7 | Disease group | pre-operation | Blood serum |
| SA400931 | CTO8 | Disease group | pre-operation | Blood serum |
| SA400932 | CTO9 | Disease group | pre-operation | Blood serum |
| SA400933 | CTO10 | Disease group | pre-operation | Blood serum |
| SA400934 | CTO11 | Disease group | pre-operation | Blood serum |
| SA400935 | CTO12 | Disease group | pre-operation | Blood serum |
| SA400936 | CTO13 | Disease group | pre-operation | Blood serum |
| SA400937 | CTO14 | Disease group | pre-operation | Blood serum |
| SA400938 | CTO22 | Disease group | pre-operation | Blood serum |
| SA400939 | CTO16 | Disease group | pre-operation | Blood serum |
| SA400940 | CTO17 | Disease group | pre-operation | Blood serum |
| SA400941 | CTO18 | Disease group | pre-operation | Blood serum |
| SA400942 | CTO19 | Disease group | pre-operation | Blood serum |
| SA400943 | CTO20 | Disease group | pre-operation | Blood serum |
| SA400944 | CTO21 | Disease group | pre-operation | Blood serum |
| SA400945 | CTO5 | Disease group | pre-operation | Blood serum |
| SA400946 | CTO23 | Disease group | pre-operation | Blood serum |
| SA400947 | CTO24 | Disease group | pre-operation | Blood serum |
| SA400948 | CTO6 | Disease group | pre-operation | Blood serum |
| SA400949 | CTO1 | Disease group | pre-operation | Blood serum |
| SA400950 | CTO4 | Disease group | pre-operation | Blood serum |
| SA400951 | CTO2 | Disease group | pre-operation | Blood serum |
| SA400952 | shotgun-CTO 1 | Disease group | pre-operation | Blood serum |
| SA400953 | shotgun-CTO 2 | Disease group | pre-operation | Blood serum |
| SA400954 | shotgun-CTO 3 | Disease group | pre-operation | Blood serum |
| SA400955 | CTO3 | Disease group | pre-operation | Blood serum |
| Showing results 1 to 63 of 63 |
Collection:
| Collection ID: | CO003787 |
| Collection Summary: | A total of 44 persons were recruited in this study: 24 CTO-PCI patients and 20 control volunteers. All the clinical samples included in the study were collected from the Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital of Fudan University and Chronic Total Occlusion Club, China (CTOCC). Ethical approval from the Zhongshan Hospital Research Ethics Committee and patient written informed consent were obtained. None of the 24 CTO patients had received any PCI treatment before. CTO was defined as thrombolysis in myocardial infarction (TIMI) with grade 0 flow, and the duration of coronary occlusion was ≥3 months 10. The 20 volunteers of suspected CTO patients in control group had no evidence of coronary stenosis or even luminal irregularities on conventional angiography and underwent a similar protocol. |
| Sample Type: | Blood (serum) |
Treatment:
| Treatment ID: | TR003803 |
| Treatment Summary: | Furthermore, lipid profiling during the preoperative and postoperative phases of CTO-PCI patients may assist in assessing preoperative risk and predicting postoperative outcomes. The evaluation of circulating lipid alterations in CTO-PCI patients throughout the perioperative period using both shotgun and MRM lipidomics showed that systematic lipid changes have significant potential for predicting and monitoring the prognostic effects of CTO-PCI. |
Sample Preparation:
| Sampleprep ID: | SP003801 |
| Sampleprep Summary: | Lipid extraction. The whole blood was kept quiescent at room temperature for 1 hr and centrifuged at 850 × g for 10 mins at 4℃ to separate the serum. A modified Bligh & Dyer method was u sed to extract lipids from the serum samples, as previously described 33, 34. In brief, 200 μL serum was subjected to a quick freeze-and-thaw five times using liquid nitrogen. 5 mL of a monophasic mixture of methanol: chloroform: formic acid (10:10:1) was then added. The mixture was shaken vigorously and incubated at -20℃ overnight. After 2.2 mL Hajra’s solution (0.2M H3PO4, 1M KCl) was added to each tube and mixed by vigorous shaking, the samples were centrifuged at 1,500 × g for 5 min. The lower CHCl3 phase was withdrawn to a new glass tube and the upper phase was re-extracted with 0.5 mL CHCl3. After the combination of CHCl3 phase, each sample was evaporated to 100 µL under nitrogen gas. A modified neutral lipid extraction method was used to extract lipids from the serum samples 35. An internal standard cocktail (Avanti Lipids Polar, Inc., USA) containing phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidic acid (PA), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), cholesterol ester (CE), triacylglycerol (TAG), diacylglycerol (DAG), sphingomyelin (SM) and ceramide (CER) was added to each sample at an amount of 10 μL per 200 μL of serum during the extraction. Concentration of each lipid class optimized for serum analysis. |
Combined analysis:
| Analysis ID | AN006017 | AN006018 |
|---|---|---|
| Analysis type | MS | MS |
| Chromatography type | Normal phase | Normal phase |
| Chromatography system | Shimadzu 20AD | Shimadzu 20AD |
| Column | Ultremex silica column (250 × 4.6 mm, 5 μm) fitted with a 2 × 4 mm silica guard cartridge (Phenomenex, Torrance, CA, USA) | Ultremex silica column (250 × 4.6 mm, 5 μm) fitted with a 2 × 4 mm silica guard cartridge (Phenomenex, Torrance, CA, USA) |
| MS Type | ESI | ESI |
| MS instrument type | Triple quadrupole | Triple quadrupole |
| MS instrument name | ABI Sciex 6500 QTrap | ABI Sciex 6500 QTrap |
| Ion Mode | POSITIVE | NEGATIVE |
| Units | peak intensity | peak intensity |
Chromatography:
| Chromatography ID: | CH004572 |
| Instrument Name: | Shimadzu 20AD |
| Column Name: | Ultremex silica column (250 × 4.6 mm, 5 μm) fitted with a 2 × 4 mm silica guard cartridge (Phenomenex, Torrance, CA, USA) |
| Column Temperature: | 16℃ |
| Flow Gradient: | The samples were then eluted with a 300 μL/min gradient as follows: 50% B from 0 to 5 min. From 5 to 30 min, B was linearly ramped up to 100%, where it remained for 10 min. From 40 to 41 min, B was returned to 50%, where it remained until the end of the run at 50 min. In neutral lipids’ quantification, the samples were then eluted with a 200 μL/min gradient as follow: 5% B from 0 to 8 min and then 25% B from 8 to 25 min. From 25 to 30 min, B was linearly ramped to 90%, where it remained for 6 min. From 35 to 40 min, B was returned to 5%, where it remained until the end of the run at 50 min. |
| Flow Rate: | 300 μL/min |
| Solvent A: | 58% Isopropyl alcohol/40% Hexane/2% 100 mM Ammonium acetate |
| Solvent B: | 50% Isopropyl alcohol/40% Hexane/10% 100 mM Ammonium acetate |
| Chromatography Type: | Normal phase |
MS:
| MS ID: | MS005728 |
| Analysis ID: | AN006017 |
| Instrument Name: | ABI Sciex 6500 QTrap |
| Instrument Type: | Triple quadrupole |
| MS Type: | ESI |
| MS Comments: | Peak identifications were performed using Analyst software (version 1.6, SCIEX). Only peaks that comprised an intensity >2% and a signal-to-noise ratio (S/N) >5 were recorded. The relative signal intensities were processed by normalization to total signal intensities. Peak changes between samples were confirmed by manual quantification. Multivariate statistical analysis and cluster analysis were accomplished by using MetaboAnalyst 4.0 (www.metaboanalyst.ca). A detailed description of the data analysis can be found in the supplemental information. |
| Ion Mode: | POSITIVE |
| MS ID: | MS005729 |
| Analysis ID: | AN006018 |
| Instrument Name: | ABI Sciex 6500 QTrap |
| Instrument Type: | Triple quadrupole |
| MS Type: | ESI |
| MS Comments: | Peak identifications were performed using Analyst software (version 1.6, SCIEX). Only peaks that comprised an intensity >2% and a signal-to-noise ratio (S/N) >5 were recorded. The relative signal intensities were processed by normalization to total signal intensities. Peak changes between samples were confirmed by manual quantification. Multivariate statistical analysis and cluster analysis were accomplished by using MetaboAnalyst 4.0 (www.metaboanalyst.ca). A detailed description of the data analysis can be found in the supplemental information. |
| Ion Mode: | NEGATIVE |
